Jaclyn Davis

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

Michael Dickinson, Pere Barba, Ulrich Jäger et al. · Cancer Discovery · 2023 · 121 citations · Full text

Medicine, Hematology, Oncology +17

A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy

David G. Maloney, Michinori Ogura, Noriko Fukuhara et al. · Blood Advances · 2020 · 34 citations · Full text

Medicine, Immunology, Oncology +13

A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)

Ian W. Flinn, Ulrich Jaeger, Nirav N. Shah et al. · Blood · 2021 · 32 citations

Medicine, Hematology, Oncology +16

YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update

Pere Barba, Mi Kwon, Javier Briones et al. · Blood · 2022 · 15 citations

Medicine, Hematology, Oncology +11

Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study

Marinus van Oers, Lukáš Smolej, Mario Petrini et al. · Blood Cancer Journal · 2019 · 13 citations · Full text

Medicine, Oncology, Pharmacotherapy +16